Prostatic Neoplasms
Research News and Information

Saturday, November 21, 2009

Clinical staging error in prostate cancer: localization and relevance of undetected tumour areas.

20 Dec 2009 OBJECTIVE: To describe the localization and to assess the clinical implications of areas of undetected prostate cancer in radical prostatectomy (RP) specimens, focusing on patients with unilaterally negative preoperative biopsy cores. PATIENTS AND ... Read more...

Expression of RIZ1 protein (Retinoblastoma-interacting zinc-finger protein 1) in prostate cancer epithelial cells changes with cancer grade progression and is modulated in vitro by DHT and E2.

29 Nov 2009 The nuclear protein methyl-transferase Retinoblastoma-interacting zinc-finger protein 1 (RIZ1) is considered to be a downstream effector of estrogen action in target tissues. Silencing of RIZ1 expression is common in many tumors. We analyzed RIZ1 ... Read more...

Annexin-A7 protects normal prostate cells and induces distinct patterns of RB-associated cytotoxicity in androgen-sensitive and -resistant prostate cancer cells.

29 Nov 2009 The tumor suppressor role of annexin-A7 (ANXA7) was previously demonstrated by cancer susceptibility in Anxa7(+/-)-mice and by ANXA7 loss in human cancers, especially in hormone-resistant prostate tumors. To gain mechanistic insights into ANXA7 ... Read more...

Latest indexed articles for 'Prostatic Neoplasms'

These are the very latest articles for this heading:

• Clinical staging error in prostate cancer: localization and relevance of undetected tumour areas. 20 Dec 2009
• Expression of RIZ1 protein (Retinoblastoma-interacting zinc-finger protein 1) in prostate cancer epithelial cells changes with cancer grade progression and is modulated in vitro by DHT and E2. 29 Nov 2009
• Annexin-A7 protects normal prostate cells and induces distinct patterns of RB-associated cytotoxicity in androgen-sensitive and -resistant prostate cancer cells. 29 Nov 2009
• Housekeeping genes in prostate tumorigenesis. 29 Nov 2009
• Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models. 29 Nov 2009
• HER3 is required for the maintenance of neuregulin-dependent and -independent attributes of malignant progression in prostate cancer cells. 29 Nov 2009
• Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel. 29 Nov 2009
• In reply to Dr. Lee: are prostate cancers created equal? 13 Nov 2009
• Radiation-induced sequelae measured by means of lymphocyte apoptosis: importance of certain single nucleotide polymorphisms: in regard to Schnarr et al. (Int J Radiat Oncol Biol Phys 2009). 13 Nov 2009
• Strategies for online organ motion correction for intensity-modulated radiotherapy of prostate cancer: prostate, rectum, and bladder dose effects. 13 Nov 2009
• Validation of temporal optimization effects for a single fraction of radiation in vitro. 13 Nov 2009
• Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation. 13 Nov 2009
• Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines. 13 Nov 2009
• Current perspectives on the Gleason grading of prostate cancer. 30 Oct 2009
• Revisiting the immunophenotype of nephrogenic adenoma. 30 Oct 2009
• Computerized utility assessment for cancer decision making: promises and pitfalls. 30 Oct 2009
• Key targets of hormone treatment of prostate cancer. Part I: the androgen receptor and steroidogenic pathways. 30 Oct 2009
• Study of robustness of IMPT and IMRT for prostate cancer against organ movement. 30 Oct 2009
• Androgen receptor as a potential sign of prostate cancer metastasis. 30 Oct 2009
• Genistein and resveratrol, alone and in combination, suppress prostate cancer in SV-40 tag rats. 30 Oct 2009

See a longer list of these articles.

Technical information about 'Prostatic Neoplasms'

Definition: Tumors or cancer of the PROSTATE.

Descriptor UI: D011471

Alternative terms: Prostatic Neoplasms; Neoplasms, Prostate; Neoplasm, Prostate; Prostate Neoplasm; Neoplasms, Prostatic; Neoplasm, Prostatic; Prostatic Neoplasm; Prostate Neoplasms; Prostate Cancer; Cancer, Prostate; Cancers, Prostate; Prostate Cancers; Cancer of the Prostate; Prostatic Cancer; Cancer, Prostatic; Cancers, Prostatic; Prostatic Cancers; Cancer of Prostate;

Related Mesh Headings: Prostatic Hyperplasia; Prostate-Specific Antigen;

Allowable Qualifiers: blood; blood supply; cerebrospinal fluid; chemically induced; classification; complications; congenital; diagnosis; diet therapy; drug therapy; economics; embryology; enzymology; ethnology; etiology; genetics; history; immunology; metabolism; microbiology; mortality; nursing; epidemiology; parasitology; pathology; physiopathology; prevention & control; psychology; radiography; radionuclide imaging; radiotherapy; rehabilitation; secondary; secretion; surgery; therapy; ultrastructure; urine; veterinary; ultrasonography; chemistry; virology;

Tree Number: C04.588.945.440.770; C12.294.260.750; C12.294.565.625; C12.758.409.750;

Technical Notes: coordinate IM with histological type of neoplasm (IM); note PROSTATIC ADENOMA see PROSTATIC HYPERPLASIA is also available